Articles

PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study

BJH - 2018, issue Abstract Book BHS, february 2018

B. Stamatopoulos , T. Smith , E. Crompot , K. Pieters , R. Clifford , M. Mraz , P. Robbe , A. Burns , A. Timbs , D. Bruce , P. Hillmen , N. Meuleman MD, PhD, P. Mineur MD, R. Firescu , M. Maerevoet MD, V. De Wilde MD, PhD, A. Efira MD, J. Philippé MD, PhD, B. Verhasselt MD, PhD, F. Offner MD, PhD, A. Heger , D. Sims , H. Dreau , A. Schuh

Read more

PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group

BJH - volume 7, issue Abstract Book BHS, january 2016

B. Mahadeb , D. Noubouossie MD, L. Rozen PharmD, T. Besse-Hamme , A. Efira MD, P. Hermans MD, PhD, B. Gulbis MD, PhD, M.A. Azerad MD, A. Demulder MD, PhD

Read more

PP4.2 The clinical relevance of imatinib (Im) plasma trough concentration in patients with chronic myelocytic leukemia (CML) in chronic phase. A Belgian retrospective study

BJH - volume 7, issue Abstract Book BHS, january 2016

F. Van Obbergh MD, L. Knoops MD, PhD, Y. Beguin MD, PhD, C. Graux MD, PhD, S. Benghiat MD, PhD, K. Kargar-Samani , D. Bauwens , A. Efira MD, C. Dubois , C. Springael MD, PhD, L. Montfort , T. Connerotte MD, A. Delannoy , P. Wallemacq

Read more

Thrombin generation in the plasma of sickle cell trait adults shows prothrombotic profile as compared to normal adults

BJH - 2014, issue Abstract Book BSTH, november 2014

L. Dewispelaere MD, B. Mahadeb , L. Rozen PharmD, D. Noubouossie MD, T. Besse-Hamer , A. Efira MD, P. Hermans MD, PhD, B. Gulbis MD, PhD, M.A. Azerad MD, A. Demulder MD, PhD

Read more

Microvesicles and cancer

BJH - volume 4, issue 1, march 2013

M.A. Azerad MD, F. Debaugnies PharmD, A. Demulder MD, PhD, D. Bron MD, PhD, A. Efira MD

Summary

Microvesicles (MV) are since quite recently recognized as forming a unique network between cells. These very little fragments (<1 µm size) are actively released from their parent cells and are able to transfer both cellular and nuclear material. Although active debate remains on how to best detect MV, rendering some results questionable, high MV levels have been reported in aggressive tumours and have been correlated with a poor clinical outcome. Some tumour cell derived MV exhibit strong tissue factor dependent procoagulant activity. Their detection could actually predict the thrombotic risk in selected cancer patients. A growing body of evidence suggests cell microvesicles to be a major link between cancer and thrombosis. Current knowledge on MV in cancer will be reviewed here.

(BELG J HEMATOL 2013;1:3–8)

Read more
X